| INTRODUCTION
Helicobacter pylori is a highly prevalent chronic infection with a worldwide prevalence around 50%. 1 It plays a key role in the pathogenesis of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and distal gastric cancer. [2] [3] [4] The Maastricht IV/Florence Consensus Report 5 recommends administering triple therapy or a bismuth or non-bismuth quadruple therapy in first-line treatment. In second-line treatment, both triple therapy containing levofloxacin and quadruple regimen containing bismuth are recommended, especially if clarithromycin has been used previously. Susceptibility-guided treatment is also an accepted strategy in first-and second-line therapy if the patient undergoes a diagnostic upper endoscopy. 6 In third-line treatment, upper endoscopy and gastric biopsies are recommended (Evidence level: 4, Grade of recommendation: A) 5 in order to prescribe the treatment according to susceptibility tests.
Although it seems to be a reasonable choice, a recent systematic review of susceptibility-guided treatment after two failure attempts noted the lack of studies comparing its efficacy with empirical treatment, and highlighted the poor efficacy in the 4 observational studies performed (PP eradication rate 80%, and ITT eradication rate 72%).
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In patients receiving initial treatment with a triple clarithromycin therapy and a second-line attempt with a levofloxacin-based triple therapy, it seems reasonable to explore third-line treatments that do not contain clarithromycin or levofloxacin. In some countries, tetracycline is not available and, at the time this study was designed, no bismuth-containing quadruple therapy was available in a single pill. This situation led researchers to explore alternative regimens.
Although it is not recommended in areas with very high metronidazole resistance, H. pylori infection treatment with amoxicillin and metronidazole associated with a proton pump inhibitor (PPI) has been extensively used in Japan, where metronidazole resistance is still low. 8 There is also evidence that by increasing the length of the treatment and the PPI and antibiotic doses, this eradication regimen can achieve PP cure rates close to 90%. [9] [10] [11] [12] It has been reported that this approach may overcome the effect of metronidazole resistance. [13] [14] [15] [16] The aim of this study was to explore the effectiveness of an empiric third-line 14-day high-dose triple therapy with esomeprazole, amoxicillin and metronidazole after a first treatment failure of a clarithromycin triple therapy (or quadruple concomitant or sequential treatment) and a second failure of a levofloxacin-containing triple therapy. Secondary endpoints were to evaluate the rate of adverse events and adherence to the prescribed eradication regimen.
| METHODS
This multicenter open-label study was conducted at eight medical the data that should be reported in observational studies using routinely collected health data). 
| Eligibility criteria
Helicobacter pylori-infected patients aged >18 years who had persistent infection after two previous treatments were consecutively included in the study. Inclusion criteria were:
by histology, rapid urease test or urea breath test (
58% of patients, all of them mild-to-moderate. Two patients (3%) did not complete >90% of the treatment because of side effects. No severe adverse events occurred.
Conclusion:
Cure rates of this 14-day schedule using high-dose esomeprazole, amoxicillin and metronidazole as a third-line eradication regimen were suboptimal, especially in patients who had received metronidazole in previous failed eradication regimens.
What's known
• Optimal third-line therapies for Helicobacter pylori are still not well established.
• Resistance to multiple antibiotics is the major factor related to treatment failure.
What's new
• Although theoretically promising, cure rates of third-line esomeprazole, amoxicillin and metronidazole (EAM) therapy have been suboptimal.
• EAM efficacy was especially low in patients who had previously received metronidazole.
of two treatment attempts with a clarithromycin-and a quinolonecontaining therapy; (iii) no allergy to the prescribed drugs; (iv) no previous gastric surgery; (v) no pregnancy or lactation; (vi) no severe systemic disease such as cirrhosis or kidney failure.
| Treatment evaluated
Patients who fulfilled these conditions received esomeprazole 40 mg b.d., amoxicillin 1 g t.d.s and metronidazole 500 mg t.d.s for 2 weeks as third-line treatment.
| Determination of H. pylori status and follow-up data
Helicobacter pylori status before treatment was determined by either histology, rapid urease test or 13 C-UBT. Patients with at least one positive test after two treatment courses were eligible for enrolment.
The primary endpoint of the study was the eradication rate.
Helicobacter pylori status was determined by 13 C-UBT and/or histology at least 4 weeks after third-line treatment. Successful eradication of H. pylori was defined as a negative histology or 13 C-UBT. When both tests were performed in one patient the infection was considered to be cured when the two tests were negative. All subjects were asked to discontinue PPI and histamine 2-blockers for ≥2 weeks before the tests. Positive 
| Statistical analysis
All the patients who were prescribed treatment were included in the ITT analysis. Patients were included in the PP analysis if they completed the follow-up test. We assumed the estimated PP effectiveness to be 80%, standard error 5%, and the desired confidence level to be 95%. Based on these assumptions, the minimum sample size to obtain an estimation of effectiveness of plus/minus 10% was 62. Assuming a 5% rate of patients lost to follow-up, the final sample size was ≥65
patients. Categorical data were compared using the chi-squared test or Fisher's exact test, as appropriate, and expressed as percentages (and 95% confidence intervals). Continuous data were compared with the Student's t-test and expressed as means ± (SD).
| RESULTS

| Patients' demographic and baseline characteristics
Sixty-eight patients were eligible for the study. Their baseline characteristics are shown in Table 1 . Mean age ± SD was 52 ± 15 years, and 57% were females. The main indications for H. pylori treatment were non-investigated dyspepsia or functional dyspepsia. The majority of patients received a first course of a 10 to 14-day triple or quadruple therapy containing clarithromycin (concomitant or sequential) and a second 10 to 14-day triple therapy including levofloxacin. All patients had at least one positive H. pylori test before the second rescue treatment, generally a 13 C-UBT. In the patients inwhom more than one test was performed, no discordances in the results were observed.
| Overall cure rates
Only one patient was lost to follow-up. Eradication of H. pylori was assessed by 13 C-UBT in 65 patients, by histology in one patient and by both in one additional patient. The PP analysis showed that 42 out of 67 patients were cured (63%, 95% CI 50-74). ITT results are shown in Table 2 .
| Cure rates in patients with previous use of metronidazole in failed eradication regimens
An extremely low initial cure rate (<60%) forced an interim analysis of the registry. Patients who received metronidazole as a part of the first-line treatment-ie, those who received concomitant or sequential quadruple therapy as first-line treatment-had very low cure rates (3 out of 8 patients, 37.5%, 95% CI 0.10-0.74). For this reason, these data were passed on to the participants in the registry and no further patients who had failed first-line metronidazole-containing quadruple therapy were included.
| Cure rates in patients who had not received metronidazole
In patients who had not been previously treated with metronidazole, 39 out of 59 patients were cured PP (66%, 95% CI: 52-78). ITT cure rates were very similar ( Table 2 ).
| Adherence and tolerance
The treatment was generally well tolerated, with but mild to moderate adverse events were reported in 39 (58%) patients (Table 3) . Five patients (8%) discontinued the treatment because of side effects, but only two of them (3%) did not complete >90% of the prescribed drugs. No hospitalisations were needed because of side effects and no deaths occurred.
| DISCUSSION
This pilot study shows that a 14-day triple therapy with high-dose esomeprazole, amoxicillin and metronidazole is safe and well- proton-pump inhibitors and amoxicillin. 24, 25 No therapy has shown a consistently high cure rate across the different studies.
In the light of our data, further investigations should evaluate how this triple therapy might be optimised. The addition of bismuth might improve cure rates 26 and may be an acceptable third-line alternative, as pilot studies of third-line triple therapies have shown.
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Another noteworthy finding is that metronidazole pretreatment further reduces the efficacy of this triple therapy. It is currently believed that using metronidazole at a high dose and for more than 10 days may overcome resistance to this agent and can cure about 70% of patients infected with a metronidazole-resistant strain. In our series, however, previous treatment with metronidazole reduced the efficacy of the therapy to very low levels, even when using long treatments and high doses of the drug. Because of our small sample size we were unable to draw definitive conclusions.
It would be interesting to explore whether metronidazole pretreatment induces high-grade resistance and thus reduces the efficacy of metronidazole-containing rescue treatments, even in the case of long-term, high-dose regimens. In this sense, the lack of susceptibility testing, especially for metronidazole, is the most important limitation to this study. Access to susceptibility data might have aided the interpretation of our results.
One of the major strengths of the study is that effectiveness was evaluated in routine clinical practice, and the ITT cure rates are fully representative of daily practice. However, as a pilot registry, the sam- least two tests. In contrast, as sensibility and specificity of UBT and histology are >95%, the Maastricht IV consensus accepts to use only one of these methods as control test. Using two tests before treatment and only one after has been conventionally accepted, but has not a clear methodological justification. In this sense, in our study all the patients were evaluated both before and after treatment by histology or UBT, both highly reliable methods. This approach, therefore, is unlikely to have significantly biased the study results. Furthermore, this approach reflects the clinical practice in a "real-life" setting.
Effectiveness of the treatment was suboptimal, but feasibility, tolerance and compliance were good. The triple therapy evaluated here might represent an advantage over susceptibility-guided treatment,
where an upper endoscopy is necessary. A recent systematic review and meta-analysis showed that third-line susceptibility-guided treatment achieved pooled ITT cure rates around 72%, not clearly superior to those achieved with the triple therapy evaluated in our study. 7 In addition, the studies in the meta-analysis included patients once the upper endoscopy and the culture was performed. Taking into account the need for an invasive test (which patients may not accept) and the fact that culture is not always successful, the effectiveness of susceptibilityguided treatment in routine clinical practice may be even lower.
In conclusion, this pilot registry shows that long triple therapy with amoxicillin and metronidazole is well tolerated and compliance is good, but its effectiveness (PP: 66%) does not exceed the cure rates obtained with other empirical therapies. Further pilot studies should evaluate whether adding bismuth to this therapy increases treatment cure rates.
